Blackstone (BX) to Provide $750M for OLN324 Phase 3 Development
Blackstone Life Sciences will provide $750M to Johnson & Johnson for the Phase 3 development of OLN324, pending the closing of J&J's acquisition of Ollin and regulatory approvals. The funds are subject to customary conditions.
How this was made

The 30-second read
Why it matters
The deal provides critical funding for a late‑stage oncology program, potentially reducing execution risk and supporting J&J's valuation, while representing a sizable capital deployment for Blackstone.
Market read
The financing is a material corporate action that could lift JNJ shares and modestly affect BX, with broader implications for biotech funding.
What to watch
Regulatory approval risk for the acquisition and Phase 3 results remain uncertain.
Background
Blackstone Life Sciences announced a $750M development‑financing commitment to Johnson & Johnson for the OLN324 Phase 3 trial, contingent on the closing of J&J's acquisition of Ollin.
Ticker impact
Blackstone will provide $750M financing to Johnson & Johnson for the OLN324 Phase 3 program tied to its pending acquisition of Ollin.
likely modest upside as the market prices in reduced funding risk
Large capital infusion directly linked to a key clinical program and acquisition reduces uncertainty for investors.
Blackstone Life Sciences commits $750M to fund Johnson & Johnson's Phase 3 program, representing a sizable capital outlay.
likely slight pressure as investors assess the cash deployment
The financing is a one‑off deal; market impact is expected to be modest and mostly driven by JNJ reaction.
Market effects
Strengthens biotech financing outlook, may encourage other investors to fund late‑stage trials.
U.S. biotech sector could see modest uplift.
Highlights continued private capital support for large‑cap pharma pipelines.
Counterpoint
The financing could signal underlying cash constraints for JNJ, suggesting deeper risk.
Key entities
- companyJohnson & Johnson
U.S. pharmaceutical giant receiving financing.
- companyBlackstone
Private‑equity firm providing the financing.
